Image

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Recruiting
18 years of age
Both
Phase 2

Powered by AI

Overview

The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival

Description

This is a phase 2, open label, single cohort, single centre, clinical trial of neoadjuvant immunotherapy with dual inhibition of PD-1 and LAG-3 immune checkpoint pathways. The hypothesis is that neoadjuvant therapy produces a higher pathological response rate (pCR) and a longer recurrence-free survival in a cohort of treatment-naïve patients with resectable stage I (≥10 mm) to stage III Merkel cell carcinoma compared to neoadjuvant nivolumab monotherapy in Checkmate 358 (n=123, NCT02488759, historical control).

Eligibility

Inclusion Criteria:

  • Aged ≥ 18 years
  • Written consent Histologically confirmed, resectable Merkel cell carcinoma with AJCC (8th ed) clinical stage I (≥ 10 mm), II, or III
  • In-transit metastases are permitted if they are completely resectable
  • Measurable disease according to RECIST 1.1 criteria
  • Tumour amenable to core biopsy
  • Previous radiotherapy permitted if there is RECIST-measurable progression of disease since the completion of radiotherapy
  • ECOG 0-1
  • Adequate organ function on blood pathology
  • Life expectancy >12 months
  • Female patients to use effective contraception during study treatment and for 5 months after last dose.

Exclusion Criteria:

  • Clinical or radiographic evidence of distant metastases
  • Contraindication to nivolumab and / or relatlimab
  • Prior anti-PD-1, CTLA-4, PDL-1 or LAG 3 antibody exposure, or an agent directed to another stimulatory or co-inhibitory T-cell receptor for any disease or any chemotherapy or experimental local or systemic drug treatment
  • Active autoimmune disease or requirement for chronic steroid therapy other than hormone replacement therapy
  • A diagnosis of immunodeficiency or chronic steroid therapy >10 mg OD prednisone or equivalent
  • Additional malignancy active within past 3 years; patients with chronic lymphocytic leukaemia can be included in this study.
  • Uncontrolled cardiovascular disease or history of myocarditis - Has had an allogenic tissue/solid organ transplant
  • Active Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
  • Known HIV
  • Pregnant or breast feeding females
  • Concurrent medical or social conditions that may prevent the patient attending assessments or procedures per schedule

Study details

Merkel Cell Carcinoma

NCT06151236

Melanoma Institute Australia

22 March 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.